Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
Keyword(s):
Keyword(s):
2015 ◽
2016 ◽
Keyword(s):
2021 ◽
Vol Publish Ahead of Print
◽
Keyword(s):
Keyword(s):
2017 ◽
Vol 72
◽
pp. S16
◽
Keyword(s):